Analysis of tumoral, stromal and glycolitic markers in the response basal cell carcinoma and Bowen disease to photodynamic therapy in real life
Background: Photodynamic therapy (PDT) is a widely-used non-surgical treatment for non-melanoma skin cancers, including basal cell carcinoma (BCC), actinic keratoses (AK), and Bowen's disease (BD). PDT has high success rates, but various factors, can influence treatment response. This study inv...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-02-01
|
| Series: | Photodiagnosis and Photodynamic Therapy |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1572100024004782 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832575544729796608 |
|---|---|
| author | L Bernal-Masferrer T Gracia-Cazaña L Najera-Botello MC Gomez-Mateo P Cerro MC Matei M Gallego-Rentero S González A Juarranz Y Gilaberte |
| author_facet | L Bernal-Masferrer T Gracia-Cazaña L Najera-Botello MC Gomez-Mateo P Cerro MC Matei M Gallego-Rentero S González A Juarranz Y Gilaberte |
| author_sort | L Bernal-Masferrer |
| collection | DOAJ |
| description | Background: Photodynamic therapy (PDT) is a widely-used non-surgical treatment for non-melanoma skin cancers, including basal cell carcinoma (BCC), actinic keratoses (AK), and Bowen's disease (BD). PDT has high success rates, but various factors, can influence treatment response. This study investigates the clinical, histological, and molecular factors that affect the efficacy of methyl aminolevulinate PDT (MAL-PDT) for BCC and BD. Methods and Patients: Prospective observational multicentric study performed between May 2019 and January 2021 with 64 patients included. Clinical data such as tumor thickness, location, and histological subtype were recorded. Immunohistochemical analysis was performed on tumor samples to assess the expression of biomarkers including p53, β-catenin, and GLUT1. Results: Tumor thickness was found to be a critical determinant of MAL-PDT response, with thicker nodular BCCs showing reduced response rates compared to thinner, superficial BCCs and BD lesions. Immunohistochemical analysis revealed that p53 positivity was associated with better treatment outcomes, while increased β-catenin and cytoplasmic GLUT1 expression correlated with resistance to PDT. On the other hand, the metabolic profile of the tumors indicated that tumors with higher glycolytic activity were less responsive to treatment, therefore, using metformin, a glycolytic inhibitor, as a potential adjuvant therapy to improve outcomes in resistant tumors should be considered. Conclusion: This study emphasizes the importance of personalized approaches in the use of MAL-PDT, tailoring treatment according to tumor-specific characteristics. Biomarkers such as p53, β-catenin, and GLUT1 can serve as predictive tools for PDT response, helping clinicians identify patients who may benefit from alternative or combined treatments to enhance therapeutic efficacy. |
| format | Article |
| id | doaj-art-c1291bc53720455ba65ac1889064cd13 |
| institution | Kabale University |
| issn | 1572-1000 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Photodiagnosis and Photodynamic Therapy |
| spelling | doaj-art-c1291bc53720455ba65ac1889064cd132025-02-01T04:11:43ZengElsevierPhotodiagnosis and Photodynamic Therapy1572-10002025-02-0151104442Analysis of tumoral, stromal and glycolitic markers in the response basal cell carcinoma and Bowen disease to photodynamic therapy in real lifeL Bernal-Masferrer0T Gracia-Cazaña1L Najera-Botello2MC Gomez-Mateo3P Cerro4MC Matei5M Gallego-Rentero6S González7A Juarranz8Y Gilaberte9Department of Dermatology, Miguel Servet University Hospital, University of Zaragoza, IIS Aragón. Zaragoza, SpainDepartment of Dermatology, Miguel Servet University Hospital, University of Zaragoza, IIS Aragón. Zaragoza, Spain; Corresponding author.Department of Pathology, Puerta de Hierro University Hospital, Universidad Autónoma, Majadahonda, Madrid, SpainDepartment of Pathology, Miguel Servet University Hospital, Zaragoza, SpainHuesca, SpainDepartment of Dermatology, Miguel Servet University Hospital, University of Zaragoza, IIS Aragón. Zaragoza, SpainDepartment of Biology, Universidad Autónoma de Madrid, Madrid, Spain; Department of Experimental Dermatology and Skin Biology, Instituto Ramón y Cajal de Investigación, IRYCIS, Madrid, SpainDepartment of Medicine and Medical Specialties, Universidad de Alcalá, 28871 Madrid, Spain; Department of Experimental Dermatology and Skin Biology, Instituto Ramón y Cajal de Investigación Sanitaria, IRYCIS, Madrid, SpainDepartment of Biology, Universidad Autónoma de Madrid, Madrid, Spain; Department of Experimental Dermatology and Skin Biology, Instituto Ramón y Cajal de Investigación, IRYCIS, Madrid, SpainDepartment of Dermatology, Miguel Servet University Hospital, University of Zaragoza, IIS Aragón. Zaragoza, SpainBackground: Photodynamic therapy (PDT) is a widely-used non-surgical treatment for non-melanoma skin cancers, including basal cell carcinoma (BCC), actinic keratoses (AK), and Bowen's disease (BD). PDT has high success rates, but various factors, can influence treatment response. This study investigates the clinical, histological, and molecular factors that affect the efficacy of methyl aminolevulinate PDT (MAL-PDT) for BCC and BD. Methods and Patients: Prospective observational multicentric study performed between May 2019 and January 2021 with 64 patients included. Clinical data such as tumor thickness, location, and histological subtype were recorded. Immunohistochemical analysis was performed on tumor samples to assess the expression of biomarkers including p53, β-catenin, and GLUT1. Results: Tumor thickness was found to be a critical determinant of MAL-PDT response, with thicker nodular BCCs showing reduced response rates compared to thinner, superficial BCCs and BD lesions. Immunohistochemical analysis revealed that p53 positivity was associated with better treatment outcomes, while increased β-catenin and cytoplasmic GLUT1 expression correlated with resistance to PDT. On the other hand, the metabolic profile of the tumors indicated that tumors with higher glycolytic activity were less responsive to treatment, therefore, using metformin, a glycolytic inhibitor, as a potential adjuvant therapy to improve outcomes in resistant tumors should be considered. Conclusion: This study emphasizes the importance of personalized approaches in the use of MAL-PDT, tailoring treatment according to tumor-specific characteristics. Biomarkers such as p53, β-catenin, and GLUT1 can serve as predictive tools for PDT response, helping clinicians identify patients who may benefit from alternative or combined treatments to enhance therapeutic efficacy.http://www.sciencedirect.com/science/article/pii/S1572100024004782Photodynamic therapyBasal cell carcinomaBowen diseaseBiomarkersResponse rates |
| spellingShingle | L Bernal-Masferrer T Gracia-Cazaña L Najera-Botello MC Gomez-Mateo P Cerro MC Matei M Gallego-Rentero S González A Juarranz Y Gilaberte Analysis of tumoral, stromal and glycolitic markers in the response basal cell carcinoma and Bowen disease to photodynamic therapy in real life Photodiagnosis and Photodynamic Therapy Photodynamic therapy Basal cell carcinoma Bowen disease Biomarkers Response rates |
| title | Analysis of tumoral, stromal and glycolitic markers in the response basal cell carcinoma and Bowen disease to photodynamic therapy in real life |
| title_full | Analysis of tumoral, stromal and glycolitic markers in the response basal cell carcinoma and Bowen disease to photodynamic therapy in real life |
| title_fullStr | Analysis of tumoral, stromal and glycolitic markers in the response basal cell carcinoma and Bowen disease to photodynamic therapy in real life |
| title_full_unstemmed | Analysis of tumoral, stromal and glycolitic markers in the response basal cell carcinoma and Bowen disease to photodynamic therapy in real life |
| title_short | Analysis of tumoral, stromal and glycolitic markers in the response basal cell carcinoma and Bowen disease to photodynamic therapy in real life |
| title_sort | analysis of tumoral stromal and glycolitic markers in the response basal cell carcinoma and bowen disease to photodynamic therapy in real life |
| topic | Photodynamic therapy Basal cell carcinoma Bowen disease Biomarkers Response rates |
| url | http://www.sciencedirect.com/science/article/pii/S1572100024004782 |
| work_keys_str_mv | AT lbernalmasferrer analysisoftumoralstromalandglycoliticmarkersintheresponsebasalcellcarcinomaandbowendiseasetophotodynamictherapyinreallife AT tgraciacazana analysisoftumoralstromalandglycoliticmarkersintheresponsebasalcellcarcinomaandbowendiseasetophotodynamictherapyinreallife AT lnajerabotello analysisoftumoralstromalandglycoliticmarkersintheresponsebasalcellcarcinomaandbowendiseasetophotodynamictherapyinreallife AT mcgomezmateo analysisoftumoralstromalandglycoliticmarkersintheresponsebasalcellcarcinomaandbowendiseasetophotodynamictherapyinreallife AT pcerro analysisoftumoralstromalandglycoliticmarkersintheresponsebasalcellcarcinomaandbowendiseasetophotodynamictherapyinreallife AT mcmatei analysisoftumoralstromalandglycoliticmarkersintheresponsebasalcellcarcinomaandbowendiseasetophotodynamictherapyinreallife AT mgallegorentero analysisoftumoralstromalandglycoliticmarkersintheresponsebasalcellcarcinomaandbowendiseasetophotodynamictherapyinreallife AT sgonzalez analysisoftumoralstromalandglycoliticmarkersintheresponsebasalcellcarcinomaandbowendiseasetophotodynamictherapyinreallife AT ajuarranz analysisoftumoralstromalandglycoliticmarkersintheresponsebasalcellcarcinomaandbowendiseasetophotodynamictherapyinreallife AT ygilaberte analysisoftumoralstromalandglycoliticmarkersintheresponsebasalcellcarcinomaandbowendiseasetophotodynamictherapyinreallife |